Targovax logoTargovax logo

  • About
    About
    Close
      • About Targovax
      • Management Team
      • Board of Directors
      • Careers
        • Director/Manager, Clinical Development
        • Scientist
  • Technology
    Technology
    Close
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
  • Pipeline
    Pipeline
    Close
      • Our pipeline
      • Development Program
        • Melanoma
        • Mesothelioma
        • Next generation viruses
  • Partnering
  • Investors & Media
    Investors & Media
    Close
      • Our strategy
      • Press releases
      • Capital markets day 2021
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Events
      • Contact
      • Subscribe
  • Governance
    Governance
    Close
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
  • Contacts
    Contacts
    Close
      • Offices
      • Investors & Media
    • About
      • About Targovax
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
        • Scientist
    • Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
    • Pipeline
      • Our pipeline
      • Development program
    • Partnering
      • TG Mutant RAS neoantigen vaccine – Available for partnering
    • Investors & Media
      • Our strategy
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Financial Reports
      • Press releases
      • Presentations
      • Prospectus
      • Debt
      • Events
      • Subscribe
      • Contact
    • Governance
      • Corporate Governance Report
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
    • Contacts
      • Offices
      • Investors & Media

    Financial Reports
    Share price
    Share price
    2020
    • 2022
    • 2021
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • All years
    Type of information
    • Annual Reports
    • Interim Reports
      Report Presentation Webcast ESEF ESEF (view XBRL)
    February 18, 2021 Annual report 2020
    February 18, 2021 Q4 Fourth Quarter
    November 5, 2020 Q3 Third Quarter
    August 20, 2020 Q2 Second Quarter
    May 7, 2020 Q1 First Quarter
    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@targovax.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@targovax.com
    (+47) 922 61 624

    Q3 interim report 2022

    Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. 

    • Report
    • Presentation
    • Webcast
    Read the report

    Subscribe

    Read more about our Protection of your personal data.
    • PRINT
    • STAY CONNECTED
    • Cookies
    • Privacy policy